Hiroshi Kakeya

5.0k total citations
253 papers, 3.5k citations indexed

About

Hiroshi Kakeya is a scholar working on Epidemiology, Infectious Diseases and Molecular Medicine. According to data from OpenAlex, Hiroshi Kakeya has authored 253 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Epidemiology, 131 papers in Infectious Diseases and 42 papers in Molecular Medicine. Recurrent topics in Hiroshi Kakeya's work include Antifungal resistance and susceptibility (81 papers), Fungal Infections and Studies (57 papers) and Antibiotic Resistance in Bacteria (42 papers). Hiroshi Kakeya is often cited by papers focused on Antifungal resistance and susceptibility (81 papers), Fungal Infections and Studies (57 papers) and Antibiotic Resistance in Bacteria (42 papers). Hiroshi Kakeya collaborates with scholars based in Japan, United States and Venezuela. Hiroshi Kakeya's co-authors include Shigeru Kohno, Koichi Izumikawa, Katsunori Yanagihara, Yoshihiro Yamamoto, Taiga Miyazaki, Yoshitsugu Miyazaki, Takayoshi Tashiro, Shigeki Nakamura, Masafumi Seki and Yoshitomo Morinaga and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Hiroshi Kakeya

242 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroshi Kakeya Japan 31 1.9k 1.9k 669 435 327 253 3.5k
Koichi Izumikawa Japan 35 2.4k 1.2× 2.5k 1.3× 803 1.2× 704 1.6× 566 1.7× 353 4.8k
Taiga Miyazaki Japan 29 1.7k 0.9× 1.5k 0.8× 536 0.8× 326 0.7× 153 0.5× 177 2.7k
Jorge Garbino Switzerland 32 2.7k 1.4× 3.0k 1.6× 369 0.6× 432 1.0× 422 1.3× 75 4.9k
P. M. Shah Germany 22 2.0k 1.1× 2.2k 1.2× 355 0.5× 289 0.7× 343 1.0× 103 3.7k
Jong Hee Shin South Korea 37 2.4k 1.2× 2.1k 1.1× 862 1.3× 166 0.4× 791 2.4× 233 4.5k
Corrado Girmenia Italy 36 3.2k 1.7× 3.0k 1.6× 331 0.5× 361 0.8× 167 0.5× 138 4.8k
Francesco Barchiesi Italy 41 3.7k 1.9× 3.0k 1.6× 900 1.3× 204 0.5× 327 1.0× 160 5.6k
Frédéric Lamoth Switzerland 39 3.3k 1.7× 2.7k 1.4× 642 1.0× 260 0.6× 146 0.4× 127 4.5k
F. Jacobs Belgium 26 1.1k 0.6× 1.2k 0.6× 426 0.6× 271 0.6× 510 1.6× 62 2.5k
Kazunori Tomono Japan 27 1.1k 0.6× 954 0.5× 484 0.7× 434 1.0× 452 1.4× 161 2.6k

Countries citing papers authored by Hiroshi Kakeya

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Kakeya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Kakeya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Kakeya more than expected).

Fields of papers citing papers by Hiroshi Kakeya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Kakeya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Kakeya. The network helps show where Hiroshi Kakeya may publish in the future.

Co-authorship network of co-authors of Hiroshi Kakeya

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Kakeya. A scholar is included among the top collaborators of Hiroshi Kakeya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Kakeya. Hiroshi Kakeya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yamada, Koichi, Kayoko Yamada, Makoto Tanaka, et al.. (2025). Impact of the COVID-19 pandemic on infectious disease treatment and infection control in Japan: A retrospective multicenter study. Heliyon. 11(12). e43490–e43490.
2.
Namikawa, Hiroki, et al.. (2025). Assessment of incidence and risk factors of COVID-19-associated candidemia using diagnosis procedure combination data. Journal of Infection and Chemotherapy. 31(5). 102689–102689.
3.
Kobayashi, Kazuhiro, et al.. (2025). Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients. The Journal of Clinical Pharmacology. 66(3). e70124–e70124. 1 indexed citations
4.
Imai, Takumi, Hiroki Namikawa, Koichi Yamada, et al.. (2024). Incidence and potential risk factors of human cytomegalovirus infection in patients with severe and critical coronavirus disease 2019. Journal of Infection and Chemotherapy. 31(1). 102452–102452. 2 indexed citations
5.
Imai, Takumi, et al.. (2024). Incidence and risk factors for coronavirus disease 2019‐associated pulmonary aspergillosis using administrative claims data. Mycoses. 67(8). e13773–e13773. 3 indexed citations
6.
Nishimura, T, Kenji Matsuo, Akihiro Kawamoto, et al.. (2023). Factors associated with the outcome of patients with COVID‐19 requiring mechanical ventilation: A single‐center observational study in Japan. SHILAP Revista de lepidopterología. 10(1). e868–e868. 1 indexed citations
7.
8.
Niki, Makoto, Hiroshi Okamura, Mitsutaka Nishimoto, et al.. (2023). Invasive fungal infection caused by Blastobotrys mokoenaii in an immunocompromised patient with acute myeloid leukemia: A case report. Journal of Infection and Chemotherapy. 30(6). 557–561. 1 indexed citations
9.
Kobayashi, Masanori, Tetsuya Watanabe, Kazuhiro Yamada, et al.. (2023). COVID-19 vaccination benefits in preventing severe disease in mild-to-moderate cases: An analysis in the first specialized hospital for COVID-19 in Japan. Respiratory Investigation. 61(2). 230–239. 2 indexed citations
10.
Tashiro, Masato, Yuya Ito, Takahiro Takazono, et al.. (2023). Prognostic Association of Liposomal Amphotericin B Doses Above 5 mg/kg/d in Mucormycosis: A Nationwide Epidemiologic and Treatment Analysis in Japan. Open Forum Infectious Diseases. 10(10). ofad480–ofad480. 4 indexed citations
11.
Namikawa, Hiroki, Yoshihiro Tochino, Keiko Ota, et al.. (2023). Mental health complaints among healthcare workers engaged in the care of COVID‐19 patients: A prospective cohort study from Japan. Journal of General and Family Medicine. 24(4). 240–246. 2 indexed citations
12.
Namikawa, Hiroki, Ken-Ichi Oinuma, Koichi Yamada, et al.. (2023). Differences in severity of bacteraemia caused by hypermucoviscous and non-hypermucoviscous Klebsiella pneumoniae. International Journal of Antimicrobial Agents. 61(5). 106767–106767. 17 indexed citations
13.
Shibata, Wataru, et al.. (2022). Body Mass Index of Elderly Patients with Normal Renal Function as a Determining Factor for Initial Vancomycin Regimen Designing. Chemotherapy. 67(3). 193–200. 2 indexed citations
14.
15.
Yamada, Koichi, Wataru Shibata, Kazuhiro Oshima, et al.. (2020). Incidental finding of neurosyphilis with intracranial hemorrhage and cerebral infarction: A case report. Journal of Infection and Chemotherapy. 27(3). 521–525. 8 indexed citations
16.
Miyazaki, Taiga, Katsunori Yanagihara, Hiroshi Kakeya, et al.. (2019). Daily practice and prognostic factors for pneumonia caused by methicillin-resistant Staphylococcus aureus in Japan: A multicenter prospective observational cohort study. Journal of Infection and Chemotherapy. 26(2). 242–251. 3 indexed citations
17.
Kakeya, Hiroshi & Shigeru Kohno. (2011). Cryptococcosis. Medical Mycology Journal. 52(3). 183–191. 1 indexed citations
18.
Takazono, Takahiro, Koichi Izumikawa, Junji Tsurutani, et al.. (2009). Lemierre's Syndrome Followed by Acute Respiratory Distress Syndrome Successfully Rescued by Antibiotics and Hemoperfusion with Polymyxin B-Immobilized Fiber. Japanese Journal of Infectious Diseases. 62(2). 133–136. 5 indexed citations
19.
Kakeya, Hiroshi, et al.. (1996). Aspergillus fumigatusが生産するほ乳動物細胞周期の新規抑制剤トリプロスタチンA,Bと他のジケトピペラジン類 1 分類,発酵,単離と生物学的性質. The Journal of Antibiotics. 49(6). 527–533. 9 indexed citations
20.
Kakeya, Hiroshi, et al.. (1996). Aspergillus fumigatusが生産するほ乳動物細胞周期の新規抑制剤トリプロスタチンA,Bと他のジケトピペラジン類 2 物理化学的性質と構造. The Journal of Antibiotics. 49(6). 534–540. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Koichi Izumikawa Breakdown of academic impact, for papers by Taiga Miyazaki Breakdown of academic impact, for papers by Jorge Garbino Breakdown of academic impact, for papers by P. M. Shah Breakdown of academic impact, for papers by Jong Hee Shin Breakdown of academic impact, for papers by Corrado Girmenia Breakdown of academic impact, for papers by Francesco Barchiesi Breakdown of academic impact, for papers by Frédéric Lamoth Breakdown of academic impact, for papers by F. Jacobs Breakdown of academic impact, for papers by Kazunori Tomono
Rankless by CCL
2026